Publications in collaboration with researchers from Oslo University Hospital (1)

2024

  1. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 403, Núm. 10421, pp. 31-43